Link → The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
[Note: Above link accesses abstact. The complete article is available without charge at Full Text PDF]
The following material is excerpted from abstract:
Objectives: To review studies on the cost consequences of compliance and/or persistence in cardiovascular disease (CVD) and related conditions (hypertension, dyslipidaemia, diabetes and heart failure) published since 1995, and to evaluate the effects of noncompliance on healthcare expenditure and the cost-effectiveness of pharmaceutical interventions.
Results: Of the 23 studies identified, 10 focused on hypertension, seven on diabetes, one on dyslipidaemia, one on coronary heart disease, one on heart failure and three covered multiple diseases. In studies assessing drug costs only, increased compliance/persistence led to increased drug costs. However, increased compliance/persistence increased the effectiveness of treatment, leading to a decrease in medical events and non-drug costs. This offset the higher drug costs, leading to savings in overall treatment costs. In studies evaluating the effect of compliance/persistence on the cost-effectiveness of pharmacological interventions, increased compliance/persistence appeared to reduce cost-effectiveness ratios, but the extent of this effect was not quantified.
Citation: N. Muszbek, D. Brixner, A. Benedict, A. Keskinaslan, Z. M. Khan (2008) The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. International Journal of Clinical Practice 62 (2), 338–351.
